Press Brief

Integrated sequencing in AML/MDS reveals prognostic constellations

BCL11A as therapeutic target in SCD: gene therapy trial

CANDOR results reveal new regimen for RRMM: KdD

Promising results for blinatumomab in younger relapsed B-ALL

Practice-changing potential from Cardinal: sutimlimab in CAD

BCMA-CD38 bispecific CAR-T cells in R/R MM

CARTITUDE-1 results: CAR-T against BCMA in R/R MM

Mosunetuzumab induces CR in B-NHL R/R to CAR-T

FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies

Hu5F9 plus rituximab to overcome resistance in refractory lymphoma

ASCEND-ing results: acalabrutinib is well-tolerated and highly effective in R/R CLL

Venetoclax with bortezomib/dexamethasone: phase 3 BELLINI results in R/R myeloma

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?

Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd

EHA 2019 program: insights from the Chair of the Scientific Program Committee